GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » YoY EPS Growth

BMRA (Biomerica) YoY EPS Growth : -14.29% (As of Aug. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Biomerica's YoY EPS Growth for the quarter that ended in Aug. 2024 was -14.29%.

Biomerica's Earnings per Share (Diluted) for the three months ended in Aug. 2024 was $-0.08.

Biomerica YoY EPS Growth Historical Data

The historical data trend for Biomerica's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica YoY EPS Growth Chart

Biomerica Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -138.46 41.94 -38.89 28.00

Biomerica Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.25 25.00 8.33 10.00 -14.29

Biomerica YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Biomerica's YoY EPS Growth for the fiscal year that ended in May. 2024 is calculated as:

YoY EPS Growth (A: May. 2024 )
=(Earnings per Share (Diluted) (A: May. 2024 )-Earnings per Share (Diluted) (A: May. 2023 ))/ | Earnings per Share (Diluted) (A: May. 2023 ) |
=(-0.36--0.5)/ | -0.5 |
=28.00 %

Biomerica's YoY EPS Growth for the quarter that ended in Aug. 2024 is calculated as:

YoY EPS Growth (Q: Aug. 2024 )
=(Earnings per Share (Diluted) (Q: Aug. 2024 )-Earnings per Share (Diluted) (Q: Aug. 2023 )) / | Earnings per Share (Diluted) (Q: Aug. 2023 )) |
=(-0.08--0.07)/ | -0.07 |
=-14.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomerica YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Biomerica's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomerica Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » YoY EPS Growth
Comparable Companies
NUWE ADMT QLIS AEMD CUTR AIMD RSLS SINT INBS VTAK ABT SYK BSX MDT XTER:SHL SZSE:300760 EW DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Website
https://www.biomerica.com
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663